Eversept Partners LP Takes $5.86 Million Position in AnaptysBio, Inc. $ANAB

Key Points

• Eversept Partners LP disclosed a new fourth-quarter stake in AnaptysBio, buying 120,927 shares worth about $5.86 million, or roughly 0.44% of the company.
• Several other institutional investors also increased their positions, while insiders were active sellers: CEO Daniel Faga and Director John P. Schmid both sold shares in late March.
• AnaptysBio reported a quarterly loss that missed EPS estimates, although revenue topped expectations; analysts currently rate the stock Moderate Buy with a consensus price target of $81.82.

Eversept Partners LP acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 120,927 shares of the biotechnology company's stock, valued at approximately $5,863,000. Eversept Partners LP owned approximately 0.44% of AnaptysBio at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ANAB. Affinity Asset Advisors LLC purchased a new stake in AnaptysBio during the fourth quarter worth about $21,559,000. JPMorgan Chase & Co. boosted its holdings in AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company's stock worth $5,497,000 after buying an additional 233,325 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in AnaptysBio by 145.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company's stock worth $11,343,000 after buying an additional 219,648 shares in the last quarter. Soleus Capital Management L.P. boosted its holdings in AnaptysBio by 214.6% during the second quarter. Soleus Capital Management L.P. now owns 321,040 shares of the biotechnology company's stock worth $7,127,000 after buying an additional 218,988 shares in the last quarter. Finally, State Street Corp boosted its holdings in AnaptysBio by 20.6% during the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company's stock worth $51,072,000 after buying an additional 180,042 shares in the last quarter.

Insider Buying and Selling

In other news, CEO Daniel Faga sold 17,679 shares of the business's stock in a transaction that occurred on Friday, March 27th. The shares were sold at an average price of $61.61, for a total value of $1,089,203.19. Following the completion of the transaction, the chief executive officer owned 495,965 shares of the company's stock, valued at $30,556,403.65. The trade was a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John P. Schmid sold 20,645 shares of the business's stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the completion of the transaction, the director directly owned 31,622 shares of the company's stock, valued at approximately $1,774,310.42. This represents a 39.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 33.50% of the company's stock.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $56.77 on Thursday. The firm has a 50 day simple moving average of $60.26 and a 200-day simple moving average of $54.84. The firm has a market cap of $1.65 billion, a PE ratio of -52.56 and a beta of 0.72. AnaptysBio, Inc. has a 1-year low of $11.40 and a 1-year high of $72.36.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. AnaptysBio had a negative net margin of 11.53% and a negative return on equity of 1,101.24%. As a group, sell-side analysts expect that AnaptysBio, Inc. will post -1.35 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has approved a stock repurchase program on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in shares. This buyback authorization authorizes the biotechnology company to buy up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board believes its stock is undervalued.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 16th. Barclays boosted their price objective on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an "overweight" rating in a report on Wednesday, May 13th. Truist Financial raised shares of AnaptysBio to a "hold" rating in a report on Wednesday, March 25th. Wedbush upped their price target on shares of AnaptysBio from $60.00 to $75.00 and gave the company an "outperform" rating in a report on Thursday, March 12th. Finally, Stifel Nicolaus upped their price target on shares of AnaptysBio from $56.00 to $85.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $81.82.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.